PATENT CLAIM ANALYSIS

Application Number: 15872571
Application Type: Utility
Filing Date: 2018-01
Publication Date: 2018-07
Patent Classification: ["514", "312000"]

Abstract:
The present invention relates to certain compounds (e.g., imidazopyrazine, imidazopyridine, imidazopyridazine and imidazpyrimidine compounds) that act as inhibitors of the MAP kinase interacting kinases MNK2a, MNK2b, MNK1a, and MNK1b. The present invention further relates to pharmaceutical compositions comprising these compounds, and to the use of the compounds for the preparation of a medicament for the prophylaxis and treatment of diseases (e.g., proliferative diseases (e.g., cancer), inflammatory diseases, Alzheimer's disease), as well as methods of treating these diseases.

Claim (Index 36):
The compound of  claim 34 , or a pharmaceutically acceptable salt thereof, wherein X 3  is N.

Metadata:
- Claim Count in Document: 11.0
- Percentile: 86.0
- Lexical Diversity: 1.84906
- Patent Class: 514.0
- Transitional Phrase Type: none
- Component Type: 0
- Foreign Priority: True
- Related Applications: ['14363718', '14517415', '15858733', '15308712', '14748990']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.8400622585614225
- 35 USC 102 Novelty (BERT): 0.5916320022136107
- Combined Prediction Score: 0.8152192329266412
- Mean Citation Score: 473.944276
- Max Citation Score: 592.0943
- Similarity Product: 405.18153188583847

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test